Strategic Market Access: Transitioning from Volume to Value in KSA (Pharmaceuticals)

(Pharmaceuticals) Saudi Arabia is abandoning external reference pricing for a value-driven reimbursement landscape engineered for state fiscal sustainability. This executive strategy program gives commercial leaders a structured overview of these macro shifts and what they mean for product strategy. The curriculum dissects the corporatization of the Ministry of Health into the Health Holding Company and the implications of activating the National Health Insurance Center. Participants learn to architect product value propositions aligned with the clinical, economic, and local-manufacturing priorities of Vision 2030. The course explores the central tension between satisfying the volume demands of centralized purchasers like NUPCO and the autonomous clinical priorities of decentralized clusters, and equips leaders to operate across both channels. Through case discussion and applied strategy work, participants learn to build messaging that resonates with public safety nets and private insurers alike. By internalizing these dynamics, commercial directors ensure that marketing and sales strategies transcend features-and-benefits selling and instead deliver compelling, evidence-anchored value stories within the Kingdom's transformed access environment.